RANOLAZINE IN ISCHEMIC HEART DISEASE

<p>Study results of a new anti-anginal drug (an inhibitor of sodium channels — ranolazine) are presented. Indications, contraindications, major clinical trials of the drug in patients with ischemic heart disease are considered.</p>

Bibliographic Details
Main Author: V. P. Lupanov
Format: Article
Language:English
Published: Столичная издательская компания 2015-12-01
Series:Рациональная фармакотерапия в кардиологии
Subjects:
Online Access:http://www.rpcardio.ru/jour/article/view/423